Atara Biotherapeutics GAAP EPS of -2.93 beats by 17.16, revenue of 40.19M beats by 5.02M
ATRA Stock | USD 10.11 0.30 3.06% |
About 57% of all Atara Biotherapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Atara Biotherapeutics suggests that some traders are interested. The current market sentiment, together with Atara Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Atara Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
Atara |
Atara Biotherapeutics beats Q3 earnings expectations with a significant increase in revenue and plans for a 35 percent decrease in operating expenses for 2024.
Read at seekingalpha.com
Atara Biotherapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Atara Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Atara Biotherapeutics Fundamental Analysis
We analyze Atara Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atara Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atara Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Atara Biotherapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Atara Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Atara Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Atara Biotherapeutics could also be used in its relative valuation, which is a method of valuing Atara Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Atara Biotherapeutics Related Equities
RCUS | Arcus Biosciences | 1.58 | ||||
KPTI | Karyopharm Therapeutics | 0.76 | ||||
CRBU | Caribou Biosciences | 0.56 | ||||
MREO | Mereo BioPharma | 0.00 | ||||
FATE | Fate Therapeutics | 0.59 | ||||
APLS | Apellis Pharmaceuticals | 2.03 | ||||
TCRX | Tscan Therapeutics | 2.36 | ||||
HRTX | Heron Therapeuti | 3.82 | ||||
ALLO | Allogene Therapeutics | 4.19 | ||||
SANA | Sana Biotechnology | 4.73 | ||||
BTAI | BioXcel Therapeutics | 4.88 | ||||
ITOS | Iteos Therapeutics | 5.59 | ||||
HOOK | Hookipa Pharma | 6.10 | ||||
ABOS | Acumen Pharmaceuticals | 8.67 | ||||
XFOR | X4 Pharmaceuticals | 12.08 |
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |